background
effect
inactiv
influenza
vaccin
iiv
laboratoryconfirm
influenza
pneumonia
older
adult
remain
establish
method
pneumonia
patient
age
year
visit
studi
hospit
chiba
japan
prospect
enrol
februari
januari
sputum
sampl
collect
particip
test
influenza
viru
polymeras
chain
reaction
assay
influenza
vaccin
effect
ive
laboratoryconfirm
influenza
pneumonia
estim
testneg
design
result
among
total
pneumonia
patient
test
posit
influenza
posit
influenza
viru
two
posit
influenza
b
viru
ive
laboratoryconfirm
influenza
pneumonia
confid
interv
ive
influenza
pneumonia
hospit
admiss
sever
pneumonia
death
ci
ci
ci
respect
subgroup
analys
ive
influenza
pneumonia
higher
patient
immunosuppress
condit
ci
without
ci
differ
patient
statin
use
statu
conclus
iiv
effect
reduc
risk
laboratoryconfirm
influenza
pneumonia
older
adult
influenza
major
public
health
concern
older
adult
influenza
infect
gener
caus
selflimit
ill
result
sever
diseas
pneumonia
older
adult
without
underli
condit
older
age
associ
higher
risk
pneumonia
mortal
influenza
patient
base
recent
estim
incid
influenza
pneumonia
relat
mortal
among
peopl
age
year
japan
per
personsyear
respect
cumul
evid
suggest
influenza
vaccin
effect
reduc
risk
medic
attend
influenza
children
adult
current
season
influenza
vaccin
recommend
older
adult
countri
howev
clinic
benefit
long
discuss
vaccin
respons
reduc
agerel
declin
adapt
immun
posit
result
report
recent
metaanalys
influenza
vaccin
reduc
medic
attend
influenza
influenzaassoci
hospit
older
adult
howev
evid
lack
protect
effect
influenza
vaccin
influenza
pneumonia
includ
primari
influenza
pneumonia
secondari
bacteri
pneumonia
studi
grijalva
influenza
pneumonia
although
major
patient
peopl
age
year
therefor
influenza
vaccin
effect
ive
laboratoryconfirm
influenza
pneumonia
older
adult
remain
establish
conduct
studi
investig
effect
trival
inactiv
influenza
vaccin
iiv
laboratoryconfirm
influenza
pneumonia
relat
outcom
adult
age
year
also
conduct
subgroup
analys
explor
differ
ive
patient
characterist
particularli
relat
immunosuppress
statu
singlecent
prospect
studi
conduct
kameda
medic
center
kmc
kamogawa
chiba
japan
part
adult
pneumonia
studi
groupjapan
apsgj
studi
apsgj
studi
multicent
prospect
studi
adult
pneumonia
conduct
four
communitybas
hospit
japan
septemb
august
investig
ive
influenza
vaccin
histori
systemat
collect
kmc
studi
pneumonia
patient
age
year
visit
kmc
februari
januari
includ
diagnosi
pneumonia
made
staff
physician
accord
clinic
sign
symptom
radiolog
find
demograph
clinic
inform
collect
patient
medic
chart
sputum
sampl
collect
patient
time
enrol
patient
unabl
cough
sputum
sputum
induc
inhal
hyperton
salin
solut
detail
studi
set
design
describ
previous
gram
stain
sputum
cultur
perform
site
sputum
sampl
transfer
institut
tropic
medicin
nagasaki
univers
test
inhous
multiplex
polymeras
chain
reaction
pcr
assay
identifi
influenza
viru
b
viral
pathogen
respiratori
syncyti
viru
rsv
human
metapneumoviru
human
parainfluenza
viru
type
human
rhinoviru
hrv
human
coronaviru
human
adenoviru
human
bocaviru
detect
limit
multiplex
pcr
assay
copi
per
reaction
report
previous
influenza
viru
subtyp
perform
influenza
aposit
sampl
via
rtpcr
influenza
ha
gene
use
previous
publish
method
patient
defin
laboratoryconfirm
influenza
pneumonia
sputum
sampl
test
posit
influenza
b
viru
pcr
influenza
pneumonia
patient
classifi
influenzaassoci
bacteri
pneumonia
sputum
sampl
microscop
purul
ie
geckler
classif
group
test
posit
bacteri
pathogen
cultur
pcr
otherwis
classifi
primari
influenza
pneumonia
testneg
design
tnd
casecontrol
studi
appli
estim
ive
unlik
convent
casecontrol
design
tnd
requir
nondiseas
control
instead
studi
design
research
collect
clinic
sampl
patient
specif
condit
eg
influenza
like
ill
classifi
patient
case
ie
influenza
test
posit
patient
control
ie
influenza
test
neg
patient
accord
influenza
test
result
tnd
less
suscept
bia
due
differ
health
careseek
behavior
among
case
control
provid
reliabl
ive
estim
recent
tnd
studi
wide
use
estim
ive
medic
attend
influenza
influenzaassoci
hospit
current
studi
primari
outcom
laboratoryconfirm
influenza
pneumonia
case
pneumonia
patient
test
posit
influenza
b
control
pneumonia
patient
test
neg
influenza
b
odd
vaccin
compar
case
control
ive
express
ratio
secondari
outcom
primari
influenza
pneumonia
influenzaassoci
bacteri
pneumonia
influenza
pneumoniarel
hospit
admiss
sever
influenza
pneumonia
influenza
pneumonia
death
japan
adult
age
year
recommend
ministri
health
labor
welfar
receiv
one
dose
season
influenza
vaccin
trival
iiv
vaccin
use
studi
period
season
quadrival
iiv
vaccin
introduc
season
highdos
adjuv
iiv
licens
japan
composit
trival
iiv
vaccin
use
studi
season
antigen
match
statu
summar
supplementari
tabl
influenza
vaccin
histori
collect
medic
record
confirm
patient
andor
guardian
patient
consid
vaccin
influenza
receiv
least
one
dose
influenza
vaccin
month
hospit
visit
durat
influenza
vaccin
hospit
visit
record
monthli
data
patient
vaccin
within
month
consid
vaccin
primari
analysi
patient
consid
unknown
influenza
vaccin
status
influenza
vaccin
histori
record
medic
chart
could
confirm
patient
guardian
group
exclud
primari
analysi
patient
categor
three
age
group
year
year
year
older
patient
disabl
statu
evalu
use
eastern
cooper
oncolog
group
perform
statu
score
bodi
mass
index
bmi
kgm
classifi
underweight
normal
overweight
chronic
condit
includ
diabet
mellitu
heart
failur
ischem
heart
diseas
cerebrovascular
diseas
liver
diseas
renal
diseas
neurolog
diseas
cancer
chronic
obstruct
pulmonari
diseas
bronchial
asthma
previou
tuberculosi
diseas
immunosuppress
statu
includ
cancer
oral
steroid
use
immunosuppress
drug
use
patient
consid
sever
pneumonia
requir
oxygen
therapi
mechan
ventil
vasopressor
admiss
period
novemb
april
consid
influenza
season
characterist
patient
compar
accord
influenza
infect
statu
ie
influenza
pneumonia
vs
noninfluenza
pneumonia
influenza
vaccin
statu
ie
vaccin
vs
unvaccin
use
chisquar
test
fisher
exact
test
categor
variabl
wilcoxon
rank
sum
test
numer
variabl
ive
estim
use
logist
regress
model
prespecifi
confound
factor
sex
age
presenc
chronic
condit
presenc
immunosuppress
smoke
statu
durat
onset
hospit
visit
period
studi
variabl
includ
final
multivari
logist
regress
model
also
consid
perform
statu
score
bmi
categori
potenti
confound
examin
ive
estim
chang
adjust
variabl
confid
interv
ci
adjust
residenti
area
level
cluster
patient
use
robust
standard
error
conduct
sensit
analys
follow
restrict
analysi
patient
visit
influenza
season
exclud
patient
vaccin
month
prior
hospit
visit
exclud
patient
vaccin
month
prior
hospit
visit
use
patient
neg
influenza
viru
posit
noninfluenza
respiratori
virus
control
use
patient
neg
virus
control
use
propens
score
adjust
includ
patient
unknown
vaccin
statu
use
multipl
imput
stratifi
analys
conduct
investig
potenti
effect
modif
patient
characterist
ie
sex
age
group
underli
condit
immunosuppress
statu
statin
use
statu
stratumspecif
ive
estim
compar
use
likelihood
ratio
test
test
interact
studi
approv
institut
review
board
irb
institut
tropic
medicin
nagasaki
univers
nagasaki
japan
irb
kameda
medic
center
chiba
japan
anonym
data
use
studi
studi
period
total
pneumonia
patient
age
year
enrol
studi
among
sputum
sampl
obtain
patient
exclud
patient
whose
influenza
vaccin
histori
unavail
patient
sputum
sampl
total
patient
elig
analys
fig
among
test
posit
influenza
viru
pcr
posit
influenza
viru
two
posit
influenza
b
viru
among
influenza
aposit
sampl
subtyp
influenza
aposit
sampl
posit
strain
noninfluenza
virus
detect
patient
hrv
lead
viru
detect
n
follow
rsv
n
noninfluenza
virus
codetect
influenzaposit
patient
detect
influenzaneg
patient
bacteri
pathogen
codetect
influenzaposit
patient
demograph
clinic
characterist
compar
influenza
pneumonia
patient
ie
case
noninfluenza
pneumonia
patient
ie
control
tabl
case
frequent
found
winter
season
control
characterist
similar
case
control
among
patient
vaccin
influenza
vaccin
patient
frequent
receiv
home
oxygen
therapi
diagnos
chronic
respiratori
obstruct
diseas
unvaccin
patient
characterist
similar
two
group
tabl
adjust
confound
ive
laboratoryconfirm
influenza
pneumonia
ci
tabl
chang
ive
estim
margin
addit
adjust
perform
statu
ci
bmi
categori
therefor
variabl
includ
final
model
sensit
analys
show
similar
result
ive
rel
higher
ci
use
patient
neg
influenza
posit
noninfluenza
virus
control
valu
almost
ident
primari
analysi
use
patient
neg
virus
ci
secondari
outcom
ive
primari
influenza
pneumonia
ci
higher
tabl
ive
influenza
pneumonia
higher
patient
immunosuppress
condit
ci
without
condit
ci
test
interact
p
ive
differ
sex
point
estim
ive
decreas
increas
age
differ
reach
statist
signific
level
test
interact
p
patient
chronic
condit
statin
use
statu
modifi
ive
iiv
effect
reduc
risk
laboratoryconfirm
influenza
pneumonia
adult
age
year
ive
higher
among
patient
immunosuppress
condit
statin
modifi
ive
knowledg
first
studi
confirm
benefici
effect
season
influenza
vaccin
laboratoryconfirm
influenza
pneumonia
older
adult
benefit
season
influenza
vaccin
older
adult
still
debat
age
group
agerel
declin
adapt
immun
result
reduc
respons
influenza
vaccin
moreov
multipl
chronic
condit
frailti
may
also
contribut
weak
immun
respons
howev
despit
observ
lower
antibodi
respons
compar
younger
adult
recent
evid
support
protect
effect
influenza
vaccin
medic
attend
influenza
older
adult
accord
systemat
review
belongia
et
al
pool
ive
ci
strain
ci
type
b
ci
strain
among
adult
age
year
darvishian
et
al
conduct
individu
particip
data
metaanalysi
tnd
studi
demonstr
influenza
vaccin
moder
effect
laboratoryconfirm
influenza
age
group
epidem
season
nonepidem
season
hand
evid
still
limit
benefici
effect
influenza
vaccin
influenzarel
sever
outcom
pneumonia
previou
studi
estim
ive
allcaus
pneumonia
influenzarel
hospit
older
adult
howev
studi
use
less
specif
outcom
may
underestim
true
ive
tnd
studi
grijalva
et
al
demonstr
overal
estim
ive
hospit
laboratoryconfirm
influenza
pneumonia
ci
howev
studi
includ
age
group
patient
age
year
analysi
restrict
patient
age
year
ive
show
posit
effect
reach
statist
signific
level
ci
therefor
author
conclud
addit
studi
need
establish
ive
pneumonia
older
adult
studi
target
age
group
demonstr
vaccin
effect
reduc
risk
laboratoryconfirm
influenza
pneumonia
ci
ive
estim
influenza
pneumonia
older
adult
may
higher
gener
expect
valu
ive
commonli
lower
sever
outcom
medic
attend
influenza
lower
older
adult
children
addit
ive
usual
lower
stain
strain
howev
estim
dissimilar
previou
report
studi
grijalva
et
al
ive
influenza
pneumonia
relat
strain
age
group
ci
anoth
studi
conduct
influenza
season
domin
circul
strain
ive
influenza
hospitaliza
use
sputum
sampl
studi
may
also
explain
high
ive
estim
identif
influenza
sputum
sampl
may
sensit
specif
upper
respiratori
tract
sampl
diagnos
influenza
pneumonia
may
provid
less
bias
ive
estim
consist
find
sensit
analys
also
support
robust
ive
estim
although
higher
ive
estim
observ
primari
influenza
pneumonia
iiv
also
effect
prevent
influenzaassoci
bacteri
pneumonia
ci
find
import
influenzabacteri
coinfect
increas
risk
sever
outcom
find
also
suggest
iiv
may
effect
prevent
influenza
pneumonia
death
howev
associ
reach
statist
signific
level
limit
sampl
size
unexpect
ive
significantli
higher
among
peopl
immunosuppress
condit
ci
among
without
ci
opposit
find
observ
studi
grijalva
et
al
includ
children
adult
vs
differ
might
least
partial
explain
lower
hiv
preval
patient
although
season
influenza
vaccin
recommend
adult
immunosuppress
condit
studi
evalu
ive
clinic
outcom
among
popul
find
provid
support
evid
current
recommend
need
confirm
futur
studi
recent
studi
suggest
statin
may
reduc
ive
medic
attend
influenza
among
older
adult
immunomodulatori
effect
howev
effect
observ
studi
although
degre
effect
remain
controversi
statin
also
known
modifi
risk
pneumonia
pneumoniarel
outcom
impact
statin
use
ive
may
differ
accord
influenza
outcom
influenza
infect
threat
older
adult
potenti
caus
pneumonia
secondari
bacteri
infect
burden
pneumonia
rapidli
increas
highincom
countri
japan
age
popul
therefor
prevent
influenza
pneumonia
import
public
health
measur
control
pneumonia
moder
effect
observ
studi
support
current
season
influenza
vaccin
polici
japan
proport
peopl
vaccin
influenza
among
adult
age
year
increas
still
remain
approxim
addit
improv
vaccin
coverag
introduct
newer
vaccin
immunogen
highdos
influenza
vaccin
must
consid
hand
must
note
pneumonia
case
influenza
pneumonia
thu
impact
influenza
vaccin
allcaus
pneumonia
limit
newer
multidimension
approach
need
reduc
pneumonia
burden
age
popul
studi
limit
influenza
vaccin
histori
document
patient
howev
sensit
analysi
use
multipl
imput
show
robust
estim
believ
exclus
patient
group
affect
ive
estim
although
potenti
confound
consid
unmeasur
confound
may
remain
recent
andrew
et
al
argu
frailti
must
consid
estim
ive
older
adult
measur
frailti
patient
measur
perform
statu
bmi
confirm
inclus
perform
statu
bmi
categori
final
model
chang
ive
estim
observ
base
analys
older
patient
age
year
fore
may
generaliz
younger
adult
final
sampl
size
small
estim
subtypespecif
ive
season
influenza
vaccin
moder
effect
laboratoryconfirm
influenza
pneumonia
adult
age
year
consid
increas
burden
pneumonia
age
popul
must
improv
influenza
vaccin
coverag
establish
newer
approach
konosuk
morimoto
report
speaker
fee
taisho
toyama
pharmaceut
pfizer
asahi
kasei
pharma
author
declar
compet
interest
